Rescue intra-arterial chemotherapy following retinoblastoma recurrence after initial intra-arterial chemotherapy

J Fr Ophtalmol. 2015 Jun;38(6):542-9. doi: 10.1016/j.jfo.2015.03.004. Epub 2015 May 14.

Abstract

Purpose: To determine the efficacy of rescue intra-arterial chemotherapy (IAC) for retinoblastoma recurrence following failed initial IAC.

Methods: Retrospective, non-comparative, interventional case series of 12 eyes in 12 patients.

Intervention: Rescue IAC employed chemotherapy agents of melphalan (5mg, 7.5mg) alone or with additional topotecan (1mg).

Main outcome measure: Tumor control and globe salvage.

Results: The median patient age at initial presentation was 16 months. At initial examination, the International Classification of Retinoblastoma grouping was group B (n=1), group D (n=7), or group E (n=4). The initial IAC was primary in 5 cases (42%) and secondary following failure of intravenous chemotherapy in 7 (58%). In all cases, initial IAC was delivered using melphalan 3mg (n=3), melphalan 5mg (n=7), or combination melphalan 5mg/topotecan 1mg (n=2) for a median of 3 cycles. The mean interval from initial IAC to recurrence necessitating rescue IAC was 5 months (median 4, range 2-10 months). Of the 12 patients, 3 (25%) had undergone previous enucleation of the opposite eye and the rescue IAC was planned for the only remaining eye. Rescue IAC was delivered for recurrent solid tumor (n=1), recurrent subretinal seeds (n=7), recurrent vitreous seeds (n=1), or combination recurrent subretinal/vitreous seeds (n=3). IAC was technically successful through the ophthalmic artery in 9 cases (75%) or the middle meningeal artery in 3 (25%). Rescue IAC involved median 3 cycles (mean 3, range 2-4 cycles) of higher dose melphalan in 4 cases (33%) or combination melphalan/topotecan in 8 (67%). At mean follow-up of 20 months (median 14 months, range 7-36 months), complete tumor control was achieved in 9 eyes (75%) and globe salvage in 8 eyes (67%). Of the 3 failure eyes, all were initially groups D or E, previously treated with initial IAC, and 2 had previous intravenous chemotherapy. There were 4 eyes that came to enucleation for persistent subretinal/vitreous seeds (n=3) or neovascular glaucoma without viable tumor (n=1). There was no case of cerebrovascular stroke, systemic metastasis, or death.

Conclusion: Rescue IAC following retinoblastoma recurrence after initial IAC provided tumor control in 75% of cases and globe salvage in 67%. Rescue IAC can be considered in children who fail initial IAC, especially if the opposite eye has been enucleated.

Keywords: Chemotherapy; Chimiothérapie; Eye; Intra-arterial chemotherapy; La chimiothérapie intra-artérielle; Rescue; Retinoblastoma; Rétinoblastome; Sauvetage; Tumeur; Tumor; Yeux.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Chemotherapy, Adjuvant
  • Child, Preschool
  • Eye Enucleation
  • Female
  • Follow-Up Studies
  • Humans
  • Infant
  • Infusions, Intra-Arterial
  • Male
  • Melphalan / administration & dosage
  • Neoplasm Recurrence, Local / diagnosis
  • Neoplasm Recurrence, Local / drug therapy*
  • Retinal Neoplasms / diagnosis
  • Retinal Neoplasms / drug therapy*
  • Retinoblastoma / diagnosis
  • Retinoblastoma / drug therapy*
  • Retinoscopy
  • Retreatment
  • Salvage Therapy*
  • Topotecan / administration & dosage
  • Treatment Failure
  • Treatment Outcome

Substances

  • Topotecan
  • Melphalan